Sied Kebir

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 576 citations · Full text

Medicine, Oncology, Pharmacology +16

Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET

Norbert Galldiks, Veronika Dunkl, Gabriele Stoffels et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 265 citations

Medicine, Oncology, Radiology +12

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O⁶-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

Ulrich Herrlinger, Niklas Schäfer, Astrid Weyerbrock et al. · Journal of Clinical Oncology · 2016 · 197 citations

Medicine, Oncology, Pharmacotherapy +15

Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma

Agnieszka Korfel, Uwe Schlegel, Ulrich Herrlinger et al. · Journal of Clinical Oncology · 2016 · 134 citations

Medicine, Oncology, Pharmacotherapy +17

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET

Sied Kebir, Rolf Fimmers, Norbert Galldiks et al. · Clinical Cancer Research · 2015 · 126 citations

Medicine, Nuclear Medicine, Oncology +17